Literature DB >> 33584721

Interleukin-1 as Innate Mediator of T Cell Immunity.

Bram Van Den Eeckhout1,2, Jan Tavernier1,2,3, Sarah Gerlo1,2.   

Abstract

The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC molecules, which allows for a specific T cell response; (2) T cell co-stimulation, which breaks T cell tolerance; and (3) secretion of polarizing cytokines in the priming environment, thereby specializing T cell immunity. The three-signal model provides an empirical framework for innate instruction of adaptive immunity, but mainly discusses STAT-dependent cytokines in T cell activation and differentiation, while the multi-faceted roles of type I IFNs and IL-1 cytokine superfamily members are often neglected. IL-1α and IL-1β are pro-inflammatory cytokines, produced following damage to the host (release of DAMPs) or upon innate recognition of PAMPs. IL-1 activity on both DCs and T cells can further shape the adaptive immune response with variable outcomes. IL-1 signaling in DCs promotes their ability to induce T cell activation, but also direct action of IL-1 on both CD4+ and CD8+ T cells, either alone or in synergy with prototypical polarizing cytokines, influences T cell differentiation under different conditions. The activities of IL-1 form a direct bridge between innate and adaptive immunity and could therefore be clinically translatable in the context of prophylactic and therapeutic strategies to empower the formation of T cell immunity. Understanding the modalities of IL-1 activity during T cell activation thus could hold major implications for rational development of the next generation of vaccine adjuvants.
Copyright © 2021 Van Den Eeckhout, Tavernier and Gerlo.

Entities:  

Keywords:  CD4+ T cells; CD8+ T cells; cancer immunotherapy; cellular adjuvant; dendritic cells; interleukin-1; vaccination

Year:  2021        PMID: 33584721      PMCID: PMC7873566          DOI: 10.3389/fimmu.2020.621931

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  296 in total

1.  IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells.

Authors:  S Nakae; M Asano; R Horai; N Sakaguchi; Y Iwakura
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

2.  Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5.

Authors:  Xiang-Ping Yang; Kamran Ghoreschi; Scott M Steward-Tharp; Jaime Rodriguez-Canales; Jinfang Zhu; John R Grainger; Kiyoshi Hirahara; Hong-Wei Sun; Lai Wei; Golnaz Vahedi; Yuka Kanno; John J O'Shea; Arian Laurence
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

3.  IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response.

Authors:  Susumu Nakae; Yutaka Komiyama; Hiroshi Yokoyama; Aya Nambu; Masaomi Umeda; Michiko Iwase; Ikuo Homma; Katsuko Sudo; Reiko Horai; Masahide Asano; Yoichiro Iwakura
Journal:  Int Immunol       Date:  2003-04       Impact factor: 4.823

Review 4.  Interleukin-1 and interleukin-1 fragments as vaccine adjuvants.

Authors:  D Boraschi; A Tagliabue
Journal:  Methods       Date:  1999-09       Impact factor: 3.608

5.  Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection.

Authors:  Nicole Schmitz; Michael Kurrer; Martin F Bachmann; Manfred Kopf
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling.

Authors:  Jihoon Chang; Patrick R Burkett; Christopher M Borges; Vijay K Kuchroo; Laurence A Turka; Cheong-Hee Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

7.  Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset.

Authors:  Marc Veldhoen; Catherine Uyttenhove; Jacques van Snick; Helena Helmby; Astrid Westendorf; Jan Buer; Bruno Martin; Christoph Wilhelm; Brigitta Stockinger
Journal:  Nat Immunol       Date:  2008-10-19       Impact factor: 25.606

Review 8.  Immunocytokines for cancer treatment: past, present and future.

Authors:  Dario Neri; Paul M Sondel
Journal:  Curr Opin Immunol       Date:  2016-04-06       Impact factor: 7.486

9.  IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3.

Authors:  Reiner K W Mailer; Anne-Laure Joly; Sang Liu; Szabolcs Elias; Jesper Tegner; John Andersson
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

Review 10.  Clinical Development of New TB Vaccines: Recent Advances and Next Steps.

Authors:  Mark Hatherill; Richard G White; Thomas R Hawn
Journal:  Front Microbiol       Date:  2020-01-30       Impact factor: 5.640

View more
  17 in total

Review 1.  Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Cell Death in ADPKD.

Authors:  Ewud Agborbesong; Linda Xiaoyan Li; Lu Li; Xiaogang Li
Journal:  Front Mol Biosci       Date:  2022-06-29

2.  Hypervirulent Klebsiella pneumoniae Strains Modulate Human Dendritic Cell Functions and Affect TH1/TH17 Response.

Authors:  Sabrina Nicolò; Giorgio Mattiuz; Alberto Antonelli; Fabio Arena; Vincenzo Di Pilato; Tommaso Giani; Ilaria Baccani; Ann Maria Clemente; Giuseppe Castronovo; Michele Tanturli; Federico Cozzolino; Gian Maria Rossolini; Maria Gabriella Torcia
Journal:  Microorganisms       Date:  2022-02-07

3.  Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication.

Authors:  Leander Huyghe; Sandra Van Lint; Bram Van Den Eeckhout; Elianne Burg; Stéphane Plaisance; Frank Peelman; Anje Cauwels; Gilles Uzé; Niko Kley; Sarah Gerlo; Jan Tavernier
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

4.  RORγt phosphorylation protects against T cell-mediated inflammation.

Authors:  Shengyun Ma; Shefali A Patel; Yohei Abe; Nicholas Chen; Parth R Patel; Benjamin S Cho; Nazia Abbasi; Suling Zeng; Bernd Schnabl; John T Chang; Wendy Jia Men Huang
Journal:  Cell Rep       Date:  2022-03-15       Impact factor: 9.423

Review 5.  Inflammasome Contribution to the Activation of Th1, Th2, and Th17 Immune Responses.

Authors:  Ekaterina Martynova; Albert Rizvanov; Richard A Urbanowicz; Svetlana Khaiboullina
Journal:  Front Microbiol       Date:  2022-03-17       Impact factor: 5.640

Review 6.  Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.

Authors:  Tobias Puengel; Hanyang Liu; Adrien Guillot; Felix Heymann; Frank Tacke; Moritz Peiseler
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

7.  A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner.

Authors:  Nader El-Sayes; Alyssa Vito; Omar Salem; Samuel Tekeste Workenhe; Yonghong Wan; Karen Mossman
Journal:  Int J Mol Sci       Date:  2022-02-03       Impact factor: 5.923

Review 8.  Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future.

Authors:  Zhengchao Zhang; Lele Miao; Zhijian Ren; Futian Tang; Yumin Li
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

9.  Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes.

Authors:  Ashok K Pullikuth; Eric D Routh; Kip D Zimmerman; Julia Chifman; Jeff W Chou; Michael H Soike; Guangxu Jin; Jing Su; Qianqian Song; Michael A Black; Cristin Print; Davide Bedognetti; Marissa Howard-McNatt; Stacey S O'Neill; Alexandra Thomas; Carl D Langefeld; Alexander B Sigalov; Yong Lu; Lance D Miller
Journal:  Front Oncol       Date:  2021-12-08       Impact factor: 6.244

10.  Immunological Responses to Transgene-Modified Neural Stem Cells After Transplantation.

Authors:  Naili Wei; Zhenxing Sun; Jimei Yu; Yanfei Jia; Peiqi Zheng; Hailiang Tang; Jian Chen
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.